BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19149758)

  • 21. Capecitabine as third line therapy in patients with advanced colorectal cancer.
    Gubanski M; Naucler G; Almerud A; Lideståhl A; Lind PA
    Acta Oncol; 2005; 44(3):236-9. PubMed ID: 16076695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced disease and new drugs.
    Frustaci S; Buonadonna A; La Mura N; Berretta M; De Paoli A
    Suppl Tumori; 2003; 2(5):S48-50. PubMed ID: 12914391
    [No Abstract]   [Full Text] [Related]  

  • 23. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Okines AF; Ashley S
    N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
    [No Abstract]   [Full Text] [Related]  

  • 24. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
    Jordan K; Kellner O; Kegel T; Schmoll HJ; Grothey A
    Clin Colorectal Cancer; 2004 May; 4(1):46-50. PubMed ID: 15207020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Van Cutsem E; Verslype C; Tejpar S
    Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
    Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G; Jauhri M; Negi A; Aggarwal S
    Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palliative chemotherapy for pancreatic malignancies.
    Mehta SP
    Surg Clin North Am; 2010 Apr; 90(2):365-75. PubMed ID: 20362792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H
    Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
    Glynne-Jones R; Dunst J; Sebag-Montefiore D
    Ann Oncol; 2006 Mar; 17(3):361-71. PubMed ID: 16500912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future treatment options with capecitabine in solid tumours.
    Wilke H
    Eur J Cancer; 2002 Feb; 38 Suppl 2():21-5. PubMed ID: 11841932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.
    Chong G; Cunningham D
    Clin Oncol (R Coll Radiol); 2005 Apr; 17(2):79-80. PubMed ID: 15830568
    [No Abstract]   [Full Text] [Related]  

  • 36. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563
    [No Abstract]   [Full Text] [Related]  

  • 37. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
    Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
    Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
    Schønnemann KR; Yilmaz M; Andersen M; Pfeiffer P
    Acta Oncol; 2011 Jan; 50(1):151-2. PubMed ID: 20843172
    [No Abstract]   [Full Text] [Related]  

  • 40. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Farkouh A; Ettlinger D; Schueller J; Georgopoulos A; Scheithauer W; Czejka M
    Anticancer Res; 2010 Dec; 30(12):5207-11. PubMed ID: 21187514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.